Component,Publication Grant Number,Publication Doi,Publication Journal,Pubmed Id,Publication Title,Pubmed Url,Publication Year,Publication Keywords,Publication Authors,Publication Abstract,Publication Assay,Publication Tumor Type,Publication Tissue,Publication Dataset Alias,Publication Accessibility,PublicationView_id,Id,entityId,Dataset View_id
PublicationView,CA227136,10.3171/2021.11.focus21587,Neurosurg Focus,35104791,The immunology of low-grade gliomas,https://pubmed.ncbi.nlm.nih.gov/35104791,2022,"Microenvironment, immunology, Low-grade Glioma, Immune Cell Infiltration","Alexander F Haddad, Jacob S Young, Jun Yeop Oh, Hideho Okada, Manish K Aghi","Low-grade gliomas (LGGs), which harbor an isocitrate dehydrogenase (IDH) mutation, have a better prognosis than their high-grade counterparts; nonetheless, they remain incurable and impart significant negative impacts on patients' quality of life. Although immunotherapies represent a novel avenue of treatment for patients with LGGs, they have not yet been successful. Accurately selecting and evalu(Read more on Pubmed)","Immunotherapy, Clinical Study",Glioma,Not Applicable,Not Applicable,Open Access,35104791,096551c9-896e-4584-b40a-716b1afe89a0,syn52564839,35104791
PublicationView,CA227136,10.1093/neuonc/noac090,Neuro Oncol,36322096,Novel intraoperative strategies for enhancing tumor control: Future directions,https://pubmed.ncbi.nlm.nih.gov/36322096,2022,"Glioma, Surgery, Glioblastoma, Ced, Imri","Alexander F Haddad, Manish K Aghi, Nicholas Butowski","Maximal safe surgical resection plays a key role in the care of patients with gliomas. A range of technologies have been developed to aid surgeons in distinguishing tumor from normal tissue, with the goal of increasing tumor resection and limiting postoperative neurological deficits. Technologies that are currently being investigated to aid in improving tumor control include intraoperative imaging(Read more on Pubmed)",Confocal Microscopy,"Glioblastoma, Glioma",Brain,Not Applicable,Open Access,36322096,69258d11-3e06-43ca-be9f-171e1789a134,syn52564839,36322096
PublicationView,CA227136,10.1093/neuonc/noac285,Neuro Oncol,36640127,Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial,https://pubmed.ncbi.nlm.nih.gov/36640127,2023,"Immunotherapy, Treatment outcome, Recurrent Glioblastoma, Convection Enhanced Delivery (Ced), Il4r, Mdna55","John H Sampson, Achal Singh Achrol, Manish K Aghi, Krystof Bankiewicz, Martin Bexon, Steven Brem, Andrew Brenner, Chandtip Chandhasin, Sajeel Chowdhary, Melissa Coello, Benjamin M Ellingson, John R Floyd, Seunggu Han, Santosh Kesari, Yael Mardor, Fahar Merchant, Nina Merchant, Dina Randazzo, Michael Vogelbaum, Frank Vrionis, Eva Wembacher-Schroeder, Miroslaw Zabek, Nicholas Butowski","Background: MDNA55 is an interleukin 4 receptor (IL4R)-targeting toxin in development for recurrent GBM, a universally fatal disease. IL4R is overexpressed in GBM as well as cells of the tumor microenvironment. High expression of IL4R is associated with poor clinical outcomes. Methods: MDNA55-05 is an open-label, single-arm phase IIb study of MDNA55 in recurrent GBM (rGBM) patients with an aggress(Read more on Pubmed)",Clinical Study,Glioblastoma,Brain,Not Applicable,Open Access,36640127,4c2ec3af-9c00-452e-b0b0-551d1bb974ec,syn52564839,36640127
PublicationView,CA227136,10.3390/cancers15051519,Cancers (Basel),36900311,Metabolic Barriers to Glioblastoma Immunotherapy,https://pubmed.ncbi.nlm.nih.gov/36900311,2023,"Metabolism, Immunotherapy, Glioblastoma, lipid metabolism, glycolysis, Tumor Microenvironment, Tryptophan Metabolism, Glutamine Metabolism","Nikita Choudhary, Robert C Osorio, Jun Y Oh, Manish K Aghi","Glioblastoma (GBM) is the most common primary brain tumor with a poor prognosis with the current standard of care treatment. To address the need for novel therapeutic options in GBM, immunotherapies which target cancer cells through stimulating an anti-tumoral immune response have been investigated in GBM. However, immunotherapies in GBM have not met with anywhere near the level of success they ha(Read more on Pubmed)",Immunotherapy,Glioblastoma,Brain,Not Applicable,Open Access,36900311,d365e430-a6c4-46f2-952c-5a9e072af82c,syn52564839,36900311
PublicationView,CA227136,10.1016/s1470-2045(22)00626-x,Lancet Oncol,36243021,Chronic convection-enhanced intratumoural delivery of chemotherapy for glioblastoma,https://pubmed.ncbi.nlm.nih.gov/36243021,2022,,"Jacob S Young, Manish K Aghi",No abstract available.,Clinical Study,Glioblastoma,Brain,Not Applicable,Open Access,36243021,4dfa277d-356f-4817-a5ad-6f8f6c005344,syn52564839,36243021
